Available Courses
Hyperkalaemia in Cardiorenal Disease – A Case Based Discussion
- Not accredited
Published:
Learning objectives
- Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
- Identify patients who would benefit from anti-hyperkalaemia medications
- Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
- Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
- Summarise current guideline recommendations on the use of potassium binding agents
Implementing Heart Failure Guidelines with Collaborative Care
- Not accredited
Published:
Learning objectives
- Appraise new updates in heart failure guideline-directed medical therapy (GDMT)
- Apply latest guideline recommendations to patient cases
- Describe barriers preventing early initiation of GDMT
- Identify the roles of nurses and other healthcare professionals to achieve optimal heart failure therapy
- Identify the importance of the nurse/cross-functional team
Incorporating GDMT and PRO Endpoints for Personalised HF Management
- 1.00
Published:
Learning objectives
- Review current GDMT in HFrEF and HFpEF
- Describe the relationship between initiation of GDMT and HF outcomes
- Prescribe GDMT according to current international recommendations
- Recall the elements of the Kansas City Cardiomyopathy Questionnaire
- Describe the clinical studies that support the use of functional and QoL measures in practice
- Initiate quality of life and functional improvement measures in routine practice
- Initiate SGLT-2 inhibitors in patients presenting with De novo HF and in patients already on other GDMT
- Adopt shared decision-making with HF patients
Individualising Antithrombotic Strategies for Established CAD
- 1.00
Published:
Learning objectives
- Summarise current guidance for choosing antithrombotic therapy in established CAD
- Describe current gaps in clinical evidence and what is missing from current guidance
- Adopt an evidence-based approach for managing patients with ACS and CCS
Medical Options for Advanced HFpEF/HFmrEF Patients: An Expert-Guided Virtual Ward Round
- 1.00
Published:
Learning objectives
- Describe the current limitations of HFmrEF/HFpEF GDMT in advanced patients
- Select appropriate patients for advanced medical therapy
- Recall recent trial data for novel therapeutic approaches
- Use expert guidance to develop an evidence-based approach to managing advanced HFmrEF/HFpEF
Multidisciplinary Approaches to Improve Pulmonary Embolism (PE) Management - Latest Clinical Data
- 1.00
Published:
Learning objectives
- Enhance clinician understanding of current PE management
- Promote the Multidisciplinary Team (MDT) approach in PE management
- Familiarise clinicians with the latest data from the PEERLESS study
Obstructive Hypertrophic Cardiomyopathy: Getting It Right First Time
- 1.00
Published:
Learning objectives
- Recall the general approach to diagnosis and stratification of HCM according to the latest guidelines and expert opinion
- Apply advanced echocardiographic methodologies to equivocal HCM diagnoses
- Select appropriate imaging modalities to facilitate accurate risk stratification
- Stratify patients based on specific risk features and disease severity
- Choose suitable treatment modalities for patients based on specific disease features and severity
Overcoming the Challenges in Optimising GDMT in HF
- Not accredited
Published:
Learning objectives
- Appraise the urgency needed in rapid initiation of GDMT to improve HF outcomes.
- Recognise barriers preventing the use of GDMT in current practice.
- Identify strategies needed to drive implementation of GDMT in clinical practice.
Most Recent
Multidisciplinary Approaches to Improve Pulmonary Embolism (PE) Management - Latest Clinical Data
- 1.00
Published:
Learning objectives
- Enhance clinician understanding of current PE management
- Promote the Multidisciplinary Team (MDT) approach in PE management
- Familiarise clinicians with the latest data from the PEERLESS study
Decoding the Future of Heart Failure — Emerging Strategies in HF with EF ≥40%: Key Takeaways from 2024
- 1.00
Published:
Learning objectives
- Summarise the long-term burden and current unmet needs for patients with HF and EF ≥40%
- Recall data on new therapies being evaluated in the HFmr/pEF population, including data from the AHA 2024 annual congress
- Describe how non-steroidal MRAs differ in their mechanism of action and elicit their benefits in HF